95 research outputs found
Stress echocardiography causes stress cardiomyopathy: A very rare complication should be reminded
A deep ATCA 20cm radio survey of the AKARI Deep Field South near the South Ecliptic Pole
The results of a deep 20 cm radio survey at 20 cm are reported of the AKARI
Deep Field South (ADF-S) near the South Ecliptic Pole (SEP), using the
Australia Telescope Compact Array telescope, ATCA. The survey has 1 sigma
detection limits ranging from 18.7--50 microJy per beam over an area of ~1.1 sq
degrees, and ~2.5 sq degrees to lower sensitivity. The observations, data
reduction and source count analysis are presented, along with a description of
the overall scientific objectives, and a catalogue containing 530 radio sources
detected with a resolution of 6.2" x 4.9". The derived differential source
counts show a pronounced excess of sources fainter than ~1 mJy, consistent with
an emerging population of star forming galaxies. Cross-correlating the radio
with AKARI sources and archival data we find 95 cross matches, with most
galaxies having optical R-magnitudes in the range 18-24 mag, and 52 components
lying within 1" of a radio position in at least one further catalogue (either
IR or optical). We have reported redshifts for a sub-sample of our catalogue
finding that they vary between galaxies in the local universe to those having
redshifts of up to 0.825. Associating the radio sources with the Spitzer
catalogue at 24 microns, we find 173 matches within one Spitzer pixel, of which
a small sample of the identifications are clearly radio loud compared to the
bulk of the galaxies. The radio luminosity plot and a colour-colour analysis
suggest that the majority of the radio sources are in fact luminous star
forming galaxies, rather than radio-loud AGN. There are additionally five cross
matches between ASTE or BLAST submillimetre galaxies and radio sources from
this survey, two of which are also detected at 90 microns, and 41 cross-matches
with submillimetre sources detected in the Herschel HerMES survey Public Data
release.Comment: MNRAS accepted and in press 9 July 2012: 28 pages, 15 Figures, 17
Table
Ulam type stability problems for alternative homomorphisms
We introduce an alternative homomorphism with respect to binary operations and investigate the Ulam type stability problem for such a mapping. The obtained results apply to Ulam type stability problems for several important functional equations.ArticleJOURNAL OF INEQUALITIES AND APPLICATIONS. 2014:228 (2014)journal articl
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-tomoderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial
An 8-sulfonamidoquinoline derivative with imidazolium unit as an extraction reagent for use in ionic liquid chelate extraction systems
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTICâHF: baseline characteristics and comparison with contemporary clinical trials
Aims:
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTICâHF) trial. Here we describe the baseline characteristics of participants in GALACTICâHF and how these compare with other contemporary trials.
Methods and Results:
Adults with established HFrEF, New York Heart Association functional class (NYHA)ââ„âII, EF â€35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokineticâguided dosing: 25, 37.5 or 50âmg bid). 8256 patients [male (79%), nonâwhite (22%), mean age 65âyears] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NTâproBNP 1971âpg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTICâHF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressureâ<â100âmmHg (n = 1127), estimated glomerular filtration rate <â30âmL/min/1.73 m2 (n = 528), and treated with sacubitrilâvalsartan at baseline (n = 1594).
Conclusions:
GALACTICâHF enrolled a wellâtreated, highârisk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation
- âŠ